세포벽의 형태학적 변화와 ABC Transporter에 기초한 벼키다리병원균 Fusarium fujikuroi CF337의 살균제 prochloraz에 대한 저항성 반응

양유리 ( You Ri Yang ),이시우 ( Si Woo Lee ),이세원 ( Se Won Lee ),김인선 ( In Seon Kim ) 한국환경농학회 2012 한국환경농학회지 Vol.31 No.1

BACKGROUND: The resistance of rice bakanae disease pathogens against the fungicide prochloraz has been reported. Understanding the resistance mechanisms is an important for better control of the pathogens. In the present study, we investigated the resistance mechanisms of Fusarium fujikuroi CF337 (CF337) against prochloraz. METHODS AND RESULTS: Morphological changes in the cell wall of CF337 grown in potato dextrose broth (PDB) with or without prochloraz was investigated by transmission electron microscopy. Growth inhibition of CF337 was examined in PDB containing prochloraz or an ABC transporter inhibitor or both of them. Cell wall thickness of CF337 grown in PDB with prochloraz was significantly increased from 80.73±1.99 nm to 193.11±7.07 nm. Significant inhibition in the growth of CF337 was observed in the presence of both prochloraz and the inhibitor, but no growth inhibition was observed in the presence of the inhibitor or prochloraz. Sequence analysis of ATP-binding cassette transporter (ABC) gene of CF337 showed 70 to 80% similarities to the genes of the pathogens resistant to other fungicides. CONCLUSION: Efflux transporter system and changes in cell wall thickness were suggested as resistance mechanisms of CF337 against prochloraz.

살균제 Prochloraz에 대한 벼 키다리병원균 Fusarium Fujikuroi CF245의 저항성 반응

양시영 ( Si Young Yang ),양유리 ( You Ri Yang ),김영철 ( Young Cheol Kim ),이세원 ( Se Won Lee ),이시우 ( Si Woo Lee ),김인선 ( In Seon Kim ) 한국환경농학회 2012 한국환경농학회 학술대회집 Vol.2012 No.-

소화제의 제형변경에 따른 전분소화력의 저하

양유리,윤성미,김재연,노환성 한국병원약사회 1999 병원약사회지 Vol.16 No.2

Digestants are made of enteric coated, multistage, or complex-form tablet for protecting against gastric deactivation and allowing delivery of predictable, high levels of biologically active enzyme to the target site for example stomach, duodenum. So when they are crushed, the stability of digestants are decreased evidently. The purpose of this study is to evaluate how much degree does the digestive action decrease especially in starch, when the formulation is changed to powder. The results are follows. Basic digestive potency per gram is little difference between capsules and tablets (3.16±0.09 (IU/g), 3.21±0.12 (IU/g) (P=0.3777, CI=95%) but capsules are more potent in digestion than tablet when they are pretreated by pH 1.2 gastric acids (0.48±0.13, 0.72±0.11, P=0.0055, CI=95%). The rate of decrease indigestive action is higher in tablet than in capsule (84±3.59%, 77.5±2.99% (P=0.0036, CI=95%). There, We made a determination that change of formulation made a greate decrease in digestive action especially enteric coated tablets.

통풍

양유리 약업신문사 2000 의약정보 Vol.2000 No.5

병원약국의 의약정보지(newsletter)에 관한 분석

최혜선,양유리,조영환,노환성 한국병원약사회 1998 병원약사회지 Vol.15 No.2

Recently, drug information services of hospital pharmacy are more important than any other time as with progress of the medicinal services and recognized the important role of hospital pharmacists. Drug information services play an important role in progressing of quality of pharmacological services by offering appropriate information to pharmacists, doctors, nurses and patients. So we made an analysis of newsletter, one of drug information services in hospital pharmacy. We collect newsletters from each hospital which publishes newsletter and analyzed the scale, required person, contents and form of each newsletter which is one of the drug information services. We hope that these results are helpful to perform better services and estimate the services.

Clozapine(Clozaril^(�))의 혈액학적 부작용 Monitoring

조유선,양유리,김재연,조영환,노환성 한국병원약사회 2000 병원약사회지 Vol.17 No.1

Clozapine is an atypical antipsychotic drug indicated for patients with schizophrenia in whom traditional antipsychotic drugs are ineffective, or in those who experience intolerable adverse effects. Clozapine can cause fatal agranulocytosis and neutropenia, so regular hematological monitoring is required. The incidence of clozapine induced agranulocytosis in Asan Medical Center and the importance of monitoring white blood cell counts in patients treated with clozapine were investigated. The hematological, demographic and dosage data of patients who received clozapine first from May 1998 to June 1999 were reviewed. Data were available for 90 patients. The incidence of neutropenia was 6.67% (n=6) and leukopenia, agranulocytosis didn't occur. Neutropenia occured within the first three months of treatment in all patients who occurred neutropenia. The intervals of drawing blood sample of inpatients and outpatients were 6.4 and 12.1 days (within 18 weeks from the first dose), and 19.3 and 33.3 days (after 18 weeks), respectively (p<0.0001). Neutropenia incidences of the two groups were not significant [7.4 and 2.9%, respectively (p=0.40)]. The rate of registering the Clozaril patient monitoring system (CPMS) was 27.78% (n=25). The monitoring intervals of CPMS and non-CPMS patients were 9.3, 9.6 days (within 18 weeks) and 29.8, 29.2 days (after 18 weeks) (p>0.05). Neutropenia incidences of the two groups were 20.0, 1.5%, respectively (p=0.006). The risk of neutropenia increased with WBC and neutrophil baseline (p<0.001) and had no relationship with sex and dose (p>0.05). The neutropenia incidence of clozapine treated patients was 6.7% and leukopenia and agranulocytosis did not occur. The relationship between regular monitoring and incidence of the hematological side effects was not statistically significant, but the use of a patient monitoring service kept the hematological risks associated with using clozapine within the acceptable limits, particularly in view of the benefits of this medication in treatment-resistant schizophrenia.

10% Intralipose^(�)와 Aminoglycosides의 Y-site 병용時 Compatibility

백진희,박옥선,양유리,김재연,노환성 한국병원약사회 1998 병원약사회지 Vol.15 No.2

For determine the stability of aminoglycosides with fat emulsion in Y-site, six aminoglycosides (amikacin, netilmicin, micronomicin, gentamicin, dibekacin and tobramycin) were added to 10% fat emulsion. All admixture were prepared and stored at room temperature under normal room lighting in plastic syringe. One volume of each drug in normal saline was added to an equal volume of 10% Intralipid. These admixtures were pH tested and visually inspected at instant, 10min, 30min, 1hr after. Emulsion particle size determined at instant, 10min, 30min, 1hr after using laser particle analyser. Although they did not result in visual breaking of all emulsions within 1hr, all drugs were incompatible with 10% Intralipid. We observed an increase in the size of the particles (1.5∼2 fold) and pH did not vary by more than 0.13 pH, but there were no admixture within permitable pH for the begin. Mean particle diameters remained relatively constant for ≤4㎛ in all the admixtures throughout the study period. Particles larger than 1 microns were observed. Therefore, in light of these results, aminoglycosides can not be administered via Y-site method with the 10% Intralipid.

5% Dextrose solution에 희석한 amphotericin B의 adverse effects : A retrospective study

김미리,한혜원,양유리,김재연,노환성 한국병원약사회 1998 병원약사회지 Vol.15 No.1

The clinical use of amphotericin B is sometimes limited by nephrotoxicity and other adverse effects. In a retrospective study, the adverse effects(nephrotoxicity, headache, fever, chills, nausea, vomiting) induced by amphotericin B of 32 patients(mean age 47, ranging from 17 to 65) treated for haematological malignancies who received amphotericin B in 5% dextrose were monitored. 47%(15/32) of the patients showed adverse effect; fever, headache, chills, nausea/vomiting, nephrotoxicity and hypokalemia showed in 22%, 13%, 9%, 9%, 60%, 25% each. The administration was interrupted by intolerance in 4 cases, by death or hopeless discharge in 5 cases, and was improved in 6 cases. Mean total dosage was 449.5㎎(11∼965㎎) and the mean duration of administration was 12.5days(1∼37days).